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Sleep paralysis (SP) is a condition where a person is paralyzed upon waking or falling
asleep. SP afflicts∼20% of people, and is also one of the typical symptoms in narcolepsy.
During SP the sleeper may experience hallucinations. Unsurprisingly, SP is associated
with great fear globally. To date, there are no published clinical trials or outcome data
for treating this condition. However, few non-pharmacological interventions have been
proposed, including cognitive behavioral approaches, and case studies showing clinical
amelioration with auto-hypnosis and Meditation-Relaxation (MR) therapy. The latter for
instance showed positive preliminary results; when applied for 8 weeks it reduced SP
frequency and anxiety/worry symptoms. With this paper we aimed to evaluate, with a
small-scale pilot study, the efficacy of MR therapy for SP in patients with narcolepsy.
Ten patients with narcolepsy and SP were enrolled in the study. Notably, MR therapy
(n = 6), applied for 8 weeks, resulted in a dramatic decrease in the number of days
SP occurred (50% reduction); and the total number of SP episodes (54% reduction)
in the last month of the study (demonstrated by large within-group effect sizes); unlike
the control intervention (deep breathing) (n = 4). These findings are preliminary and
exploratory given the small sample. Nonetheless, they represent the first proof of concept
at providing empirically-guided insights into the possible efficacy of a novel treatment for
frequently occurring SP. Although the study was conducted in patients with narcolepsy
we cautiously suggest that the findings may generalize to individuals with isolated SP.
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INTRODUCTION
Sleep paralysis (SP) is a state of atonia—skeletal muscles paralysis—occurring at sleep onset and
offset. While temporarily immobilized, the person is acutely aware of his/her surroundings (i.e.,
semi or fully conscious) (1–3). SP commonly occurs in narcolepsy; a sleep disorder involving
excessive daytime sleepiness, cataplexy and other untimely manifestations of rapid-eye-movement
(REM) sleep such hypnagogic hallucinations and SP (4). SP is also prevalent in the general
population, afflicting∼20% of people (1, 5, 6).
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Hypnogogic or hypnopompic hallucinations may occur
during SP and can involve all sensory modalities (7). Strikingly,
SP experiencers often report being terrorized by dangerous
bedroom intruders (8, 9). Supernatural interpretations of SP are
found worldwide and often reflect the cultural background of the
population in question.
In terms of neurophysiology, SP represents a REM sleep
parasomnia reflecting the dissociation between REM sleep and
wakefulness, with the concurrent presence of REM sleep muscle
atonia, wakefulness consciousness, and, eventually REM dream
mentation (1). SP occurs at the transition between wakefulness
and REM sleep in narcolepsy patients—or in otherwise healthy
subjects (10). Polysomnographic studies disclosed the co-
occurrence of wakefulness features and REM sleep during SP
episodes (11, 12). SP ranges in duration from a few seconds up
to 20min, although under paralysis patients are not accurate in
such subjective judging of the passing of time (13).
SP in the general population may be triggered by sleep
deprivation (14), and is more frequent in psychiatric conditions
like post-traumatic stress disorder (15). Unsurprisingly, SP is
linked to excessive fear, which persists after continual exposure
to the event (16, 17).
Notwithstanding the trepidation and anxiety associated
with the experience, to date there are no published clinical
trials or outcome data for treating this condition. However,
few non-pharmacological interventions have been proposed
including cognitive behavioral approaches (18, 19). Moreover,
case studies have shown clinical amelioration with auto-hypnosis
(13), and Meditation-Relaxation (MR) therapy (20). Only a
limited number of patients report a severe enough condition
that would allow for the off-label use of antidepressants
(21, 22). Thus, most sufferers would benefit from a non-
pharmacological intervention.
MR therapy—a simple (non-invasive) and direct 4-step
psychological intervention—was recently proposed for SP (20).
The aim of this pilot study was to explore the preliminary efficacy
of MR therapy for SP (applied for 8 weeks) in patients with
narcolepsy, compared to deep breathing techniques. A secondary




The study was conducted at the Center for Narcolepsy of the
University of Bologna/IRCCS Istituto delle Scienze Neurologiche
di Bologna, Italy and approved by the ethics committee at the
CE-AVEC Independent Ethical Committee, Area Vasta Emilia
Centro. Patients provided written consent. Participants met
criteria for narcolepsy (type 1 and 2) based on polysomnography,
Multiple Sleep Latency Test (MLST) and CSF hypocretin level
testing. Patients had to have experienced SP at least four times in
the last month. The study included ten patients (female = 40%;
age: M = 27.8, SD = 12.2) (Two patients were <18 years old;




SP was assessed using the Sleep Paralysis Experiences and
Phenomenology Questionnaire (SP-EPQ) (23–25).
Daily Journal (Outcome Variables)
Each day during the study (12 weeks), participants rated their SP
occurrence, perceived duration (seconds), fear associated with SP,
and disturbance caused by hallucinations (on a ten-point scale).
Baseline Measures of Mood/Anxiety
Participants completed the following validated measures: the
Beck Depression Inventory-II (BDI-II) (26), Spielberger State-
Trait Anxiety Inventory (STAI-S/T) (27), and Penn State
Worry Questionnaire (PSWQ) (28). The Italian versions were
completed (29–31).
Intervention
MR therapy is a psychological treatment for SP, comprised of
the following steps applied directly during the attack: Step I:
Reappraisal of the meaning of the attack; Step II: psychological
and emotional distancing; Step III: inward focused-attention
meditation; Step IV: Muscle relaxation [for details see (20)]. The
control intervention was identical, except participants engaged
in deep breathing instead; entailing slow deep breaths, while
repeatedly counting from 1 to 10. This is an active control
(breathing-distraction exercise) rather than a placebo.
Procedure
SP experiencers were recruited at the Outpatient Clinic for
Narcolepsy and assigned to either the MR therapy or control
group (open label study design). Participants were orally
administered the SP-EPQ to assess their SP (e.g., frequency and
features), and were instructed to keep daily a journal for 4 weeks
as a baseline assessment of SP occurrence, duration and emotions
(see above) and email this to the researcher each week. After
the 4 weeks, participants completedmood/anxiety questionnaires
and were taught the therapy techniques (i.e., practiced them
with the experimenter), and instructed to rehearse these during
ordinary wakefulness (simulating a SP attack), twice a week
for 15min. These instructions (e.g., treatment techniques) were
administered in person or via video call. Participants then
initiated the treatment which lasted 8 weeks. They kept the daily
journal during the entire study period (12 weeks).
Statistics
Exploration of the link between SP frequency and hallucinatory-
induced disturbance and mood/anxiety symptoms were analyzed
using a Pearson correlation test. Independent sample t-tests
were used to analyze baseline group differences on outcome
variables. Specific hypotheses pertaining to MR therapy and
control intervention were analyzed using focused directional
paired sample t-tests.
For test of a priori hypotheses (i.e., one-tailed t-tests), the
Benjamini and Hochberg’s (32) false discovery rate (FDR) was
applied to correct for potential Type I errors. The FDR was set
at q < 0.15, based on guidelines in the field (33). The corrected
significance level/critical value was 0.045. Displayed P-values
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TABLE 1 | Means and standard deviations for outcome variables pre and post intervention.
Condition MR therapy (n = 6) Control intervention (n = 4)
Pre Post Pre Post
M (SD) M (SD) M (SD) M (SD)
Days with SP 11.00 (3.95) 5.50 (1.64) 4.25 0.50 4.50 1.00
Total SP 14.00 (7.38) 6.50 (3.02) 4.50 0.58 5.25 0.96
Fear of SP 4.22 (2.41) 3.63 (1.47) 2.15 2.67 1.67 2.61
Duration of SP (seconds) 361.61 564.49 200.66 273.30 182.31 212.94 303.40 498.83
Hallucination disturbance 7.29 3.02 4.79 2.04 3.96 3.27 4.48 4.00
Note: M, mean; SD, standard deviation; n, sample size. “Pre” = average daily journal ratings during the baseline assessment period (4 weeks before commencing treatment); “Post” =
ratings during the last 4 weeks of treatment (i.e., week 5 to 8 of the treatment period). “Days with SP”= days that SP occurred; “total SP”= total number of SP occurrences. “Fear of SP”
= fear associated with SP; “Hallucination disturbance” = disturbance caused by SP hallucinations. “Fear of SP” and “hallucination disturbance” were rated on a ten-point Likert scale.
are raw; designated significant/non-significant after applying the
correction (34). Exploratory/baseline analyses were not corrected
for multiple comparisons, which is unnecessary (35).
The distribution of residuals was checked using the Shapiro-
Wilk test and Q-Q plots for all measures. Residuals sometimes
departed from normality. Given the F/t-test is overall robust to
violations (36), the data were analyzed with those caveats.
RESULTS
Baseline/Pre-treatment Period (Initial 4
Weeks)
Features of SP
The patients (n = 10) experienced SP on average 8.30 days
(SD = 4.57) total, and 10.20 (SD = 7.38) SP episodes in the
last month (i.e., during the baseline period). They reported
being paralyzed on average 289.89 sec (SD = 448.01). Patients
tended to hallucinate during SP (on average in 66% [SP
with hallucinations/total SP] of cases in the last month). SP
hallucinations often occurred upon awakening from sleep (51%),
and less frequently upon falling asleep (14%); a proportion of
SP episodes occurred during “sleep” (i.e., neither at onset nor
offset; 24%).
SP, Hallucinations and Mood
The number of SP episodes in the last month did not correlate
with depression, anxiety and worry symptoms (i.e., during
the baseline period). Disturbance caused by SP hallucinations
correlated with depression (r = 0.69, p = 0.039) and worry
symptoms (r = 0.69, p = 0.039) unlike anxiety (there was a
trend for trait anxiety: r = 0.58, p = 0.099) (one patient did not
complete these questionnaires: n= 9).
Treatment
Baseline Difference
Participants did not differ on outcome variables (fear, perceived
duration of SP, and disturbance caused by hallucinations) except
that participants in the MR therapy group reported a greater
number of days with SP (t5.24= 4.14, p= 0.008) and total number
of SP (t5.09 = 3.14, p = 0.025) in the last month (during the
baseline period).
MR Therapy Pre-post
There was a reduction in the number of days with SP (t5 = 4.68, p
= 0.0025, one-tailed, d= 1.91) and total number of SP (t5 = 3.86,
p = 0.006, one-tailed, d = 1.57) in the last month pre-post MR
therapy. The average fear of SP (t5 = 0.57, p = 0.298, one-tailed,
d= 0.23) and perceived duration of SP (t5 = 1.33, p= 0.121, one-
tailed, d = 0.54) in the last month were unchanged; there was a
notable tendency toward reductions in the disturbance caused by
hallucinations (t5 = 2.01, p= 0.051, one-tailed, d = 0.82).
In the control condition, the number of days with SP (t3 =
−0.52, p = 1.28, one-tailed, d = −0.26) and total number of SP
(t3 = −1.57, p = 0.44, one-tailed, d = −0.78) in the last month;
fear (t3 = 2.80, p = 0.136, one-tailed, d = 1.40) and perceived
duration (t3 = −0.83, p = 0.936, one-tailed, d = −0.41) of SP,
and disturbance caused by hallucinations in the last month (t3 =
−0.92, one-tailed, p= 0.850, d=−0.46) were unchanged [Means
and standard deviations are displayed in Table 1; key findings
are shown in Figure 1; data points plotted for individual patients
[pre-post treatment] are displayed in Figure 2].
DISCUSSION
This small-scale pilot study yields novel findings with clinical
implications. MR therapy resulted in a dramatic decrease in
the number of days SP was experienced (50% reduction),
and total number of episodes (54% reduction) in the last
month of the study (illustrated by large within-group effect
sizes). There was also a noteworthy (p = 0.05) trend toward
reductions in the disturbance caused by SP hallucinations
(a 34% reduction in self-report ratings, with a large effect
size). Given the small sample size, p-values should be
interpreted cautiously, and effect sizes should take priority.
These effects were not observed in the control intervention
where the occurrence of SP and associated negative emotional
states were unchanged. Overall, these preliminary findings
suggest that MR therapy potentially constitutes a promising
treatment option for SP; pending confirmation in randomized
clinical trials.
That MR therapy was applied by the patients in their home
environment is notable. Given the simplicity of MR therapy,
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FIGURE 1 | Days with SP and total number of SP in the last month pre-post MR therapy and control intervention (deep breathing). “Pre treatment” reflects the
baseline assessment period (4 weeks before commencing treatment); “Post treatment” reflects the last 4 weeks of treatment (week 5 to 8 of the treatment period).
*Denotes a statistically significant result.
it lends itself to internet- and smartphone-based delivery; e.g.,
where therapy instructions are administered online, and remotely
overseen by a clinician, who can intervene promptly when
necessary. As noted, in this study, in some cases for logistic
reasons therapy was delivered via video call. In brief, this low-
cost and accessible intervention may facilitate early intervention
(prevent SP from becoming chronic and possibly spiral into
psychopathology), and is potentially suitable for poorly resourced
settings and low-income countries with restricted access to health
care. This approach may be of valuable utility also in periods
such as the current COVID-19 pandemic when face-to-face
interventions are limited.
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FIGURE 2 | Days with SP and total number of SP in the last month pre-post MR therapy and control intervention (deep breathing). “Pre treatment” reflects the
baseline assessment period (4 weeks before commencing treatment); “Post treatment” reflects the last 4 weeks of treatment (week 5 to 8 of the treatment period).
In the current study, consistent with research in general
populations, disturbance caused by SP was associated
with elevated psychopathology (depressive and worry)
symptomatology. These findings are of clinical value. They
suggest that SP-associated psychological disturbance may
contribute to overall emotional instability in narcolepsy (37).
It is also conceivable that elevated psychopathology symptoms
might increase the tendency to catastrophize SP hallucinations.
As such, applying psychological treatments to specifically target
catastrophic cognitions associated with SP-related fears (e.g.,
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combined with direct SP treatments) may help improve these
patients’ emotional well-being (reduce distress) and effectively
their global functioning (38).
This novel venture sheds light on the experience of SP in
narcolepsy. Reminiscent of the general population, patients’ self-
estimated duration of SP was ∼5min, occurred most often
at sleep offset, and a comparable proportion of individuals
hallucinated during the event [e.g., 66 vs. 72% in the general
Italian population, see (25)]. Taken together, SP in narcolepsy
and the general population appear to be phenomenologically
indistinguishable, and further studies are needed to directly
compare their features.
The patients in this study relied on a daily journal to rate
their SP occurrence, duration and emotions which constitutes
a strength; i.e., that they kept a journal not only during the
treatment (8 weeks), but also prior during baseline assessment
(4 and 12 weeks total). In contrast, retrospective accounts of
such physiological and psychological states may lack precision.
The study has limitations. Since it was conducted in narcolepsy
patients the findings may possibly generalize to isolated SP
patients; this should be explored further (given that SP in
narcolepsy, unlike ISP, is within the context of hypocretin
deficiency typical of narcolepsy). Also, while the reduction
in SP following MR therapy was striking (as noted, a 54%
monthly reduction), we cannot rule out that pre-existing higher
frequency/severity of SP may have accounted for its superiority
relative to the control intervention. Indeed, future research
(randomized controlled trials) should actively match groups
based on clinical severity to rule out a threshold effect; that we
did not do so constitutes a limitation. In this study, patients
were assigned to the two groups in a non-randomized, open label
fashion; however, future studies should ensure proper allocation
concealment to prevent potential selection bias. Finally, future
sufficiently powered studies should assess the effect of therapy
on a greater number of outcome variables (e.g., related to
hallucinations and mood). We hasten to add that these findings
are preliminary given the small sample. Nonetheless, they
represent the first attempt at providing (empirically-guided)
insights into the possible efficacy of a novel treatment for chronic
SP—a condition all too often overlooked by clinicians and
researchers alike.
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